Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
TG Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
B-cell non-Hodgkin lymphoma (NHL) including Richter's Transformation (RT) and transformed follicular lymphoma (FL), that warrants systemic therapy
Chronic Lymphocytic Leukemia (CLL), that warrants systemic therapy as defined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) (Hallek 2018)
Treatment Status:
1. NHL subjects: relapsed to or refractory after at least two prior standard systemic therapies (excluding antibiotics)
2. RT subjects: relapsed or refractory after at least two prior lines of therapy for CLL/ Small lymphocytic lymphoma (SLL) or RT
3. CLL subjects: relapsed to or refractory after at least two prior standard therapies
Measurable disease defined as:
1. NHL (including SLL): at least 1 measurable disease lesion \> 1.5 centimeters (cm)
2. CLL: at least 1 measurable disease lesion
You may not be if
Prior therapy with any agent blocking the CD47/SIRPα pathway or any previous CD19 targeting therapy,
Subjects receiving cancer therapy (i.e. chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) or any investigational drug within 21 days of Cycle 1 Day 1.
Prior autologous stem cell transplant (SCT) within 6 months.
